Northland Securities analyst Suraj Kalia maintained a Buy rating on Strata Skin Sciences Inc (SSKN) today and set a price target of $7. The company’s shares closed yesterday at $2.72.
Kalia observed:
“We note that fully audited results for Q2-19 are not available, and there seems to be a delay in the filing of docs, due primarily to some discrepancies related to historical contingent and potential liabilities relates to state sales and use taxes, and some non-cash derivative acctg treatment for debentures issued in 2015. Hence, our models still do not reflect the actuals for the reasons cited above.”
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 9.5% and a 57.9% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Obalon Therapeutics Inc.
Currently, the analyst consensus on Strata Skin Sciences Inc is a Moderate Buy with an average price target of $6.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.88 and a one-year low of $1.86. Currently, Strata Skin Sciences Inc has an average volume of 58.13K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STRATA Skin Sciences, Inc. is a medical technology company, which engages in the design, development, and commercializing of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
